We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Verici Dx Plc | VRCI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.75 | 07:37:51 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.75 | 7.75 | 7.75 | 7.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 21/2/2024 12:19 by bmcollins @timboYour reasons on why Unicorns purchase is not "passive" is precisely why I posted, having been a long term investor in vct's (including Unicorn)I couldn't,(still can't) understand why there has been no reaction. Of course Unicorn had to pay the full price, it is their investors who you correctly pointed out that recieve the 30% rebate through tax relief and, again as you pointed out, the vct can buy under certain circumstances but once bought they could sell the next day if their is a bid, say. Unicorn is a long standing vct manager so if they show this confidence why do we shareholders seem so lonely here ? I just can not figure it out. The capital raise was a success all round which shows shrewd judgement, imho, by the board. Patience is truly a virtue. |
Posted at 21/2/2024 11:59 by timbo003 Also worth noting that unlike EIS investors, VCTs do not have a minimum holding period for investee companies (for EIS investors it is 3 years). VCT shareholders do however have to hold their VCT shares for 5 years to retain the 30% tax break. |
Posted at 21/2/2024 11:06 by toffeeman Unicorn paid 6.3p per share.They are uninterested in the share price over the next 5 years. If the company is still independent then they may be paying dividend by then and the VCT pays them to their shareholders tax free. If the company is acquired then Unicorn can pay out a special divi to their shareholders which again is tax free. Treat Unicorn as a passive investor with no impact on the share price. |
Posted at 13/2/2024 16:44 by bmcollins @ToffeeSadly us private investors are at the absolute bottom of the queue. Welcome to AIM... |
Posted at 24/1/2024 07:59 by adorling Good move by Management to raise £5.5 million in funds to accelerate product development and partnering strategy and impressed with just an 11% price discount. Also pleased that retail investors can participate which I intend to do.Post raising and approval cash runway will be well into 2026 so takes that question of the cash situation away. |
Posted at 08/1/2024 09:19 by adorling Proving to be one of my best investments ever. If AGL can rise 130% in a day then as VRCI’s Tutivia & Clarava commercialise (with the significant firepower of Thermo Fisher) then I am sure we will also prove to rise by such levels. Just buy in a SIPP or ISA and be patient (so hard for inexperienced investor) for multi-bag rewards to materialise. |
Posted at 24/11/2023 16:24 by bmcollins Well after the excellent investor presentation on Wednesday pm who would have thought we would be at 9p to 9.5p just before the close, yes I have added, I just wonder why buyers appear here to be as rare as rocking horse manure ? |
Posted at 03/10/2023 12:20 by wan As indicated further above, I am at a pivotal point in terms of staying invested in Verici.Food for thought: Verici has experienced a wide range of delays compared to most of their guidance, which has shaken investor confidence in relying on current and future guidance. Given that apparently the house broker has forecast the closing net cash position at December 2023 of $0.8m, but with Verici maintaining current guidance of a cash runway until mid-2024 as coming from higher than expected research related revenues, one would assume that such additional revenues, given the indicated overheads/spending, to be in the order of at least $5m, so one could assume that there must be a better than reasonable chance of contract announcements to follow. Time will tell, but patient investors are surely due something tangible and more reliable. |
Posted at 06/7/2023 07:52 by wan I also note todays news regarding Verici's Investor Presentation next week that will also include a strategic update. |
Posted at 31/5/2023 11:53 by wan The combination of the following may be a case of 2+2 = 6, so investors should conduct their own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate.I will keep this as short as possible as the amount of connected information is extensive! A few quick recaps: Verici Dx is spearheading deep sequencing analytical methodologies along with AI machine learning computational technology to advance the prognostic and diagnostic capabilities in a suite of assays in transplant care. Verici Dx Drives Innovation with Next-Generation Sequencing for Kidney Transplant Prognosis Using Illumina Connected Analytics on AWS. Parallel processing on the cloud accelerates personalized diagnostic testing. Exploring strategic options: Verici Dx continues to execute the commercial introduction of Tutivia(TM), the Company's first product for kidney transplant rejection, with first revenues in FY 2023 and is exploring strategic options to increase sales distribution and launch its second lead product, Clarava(TM) by the end of the year. Recall Verici's two key patents recently granted in the US - The patents cover broad molecular methods for predicting and diagnosing subclinical and clinical acute rejection, both pre- and post- kidney transplant by algorithmic analysis of gene sets and underpin both of Verici Dx's lead products, Tutivia(TM) and Clarava(TM), and provide protection until 2036 and 2039 respectively. The patents underpinning Tutivia(TM) have also been previously granted in Europe, China and Australia. These products use a weighted pattern of RNA biomarkers (signature) to assess the risk of rejection by the kidney transplant recipient and to assess rejection earlier and more reliably than other currently available methods. Verici Dx continues to file additional patents reflecting novel refinements to its predictive RNA signatures and methodologies driven by advanced machine learning techniques. Prior to this I was aware that CareDx was developing a gene expression profiling assay for a kidney transplant tests, using next-generation sequencing on a Illumina-based platform specifically targeted at RNA sequencing technology. And I note the following (among other CareDx events) which is perhaps healthy competition or perhaps alignment (coincidentally? also on June 5th) - Monday, June 5, 2023 12:15 - 1:15 PM PDT Location: Grand Ballroom̴ SATELLITE SYMPOSIUM An Evolving Standard of Care: Artificial Intelligence and Molecular Diagnostics Hear from experts in the field of artificial intelligence and molecular diagnostics, as they discuss the integration of these technologies into clinical practice and their impact on patient outcomes. Food for thought at least, and CareDx might not be the only suitor/strategic partner given Verici's significant new patents bolstering their intellectual property portfolio, their robust validation data/results and indeed their forthcoming clinical results and clinical trial results. 'Further' time will tell! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
